Press Releases Press Releases

Emmaus Life Sciences Issues Statement In Response to Announcement by AFH Holding & Advisory

10.10.2012.

Emmaus Life Sciences, Inc., a specialty pharmaceutical and
regenerative medicine company, today issued the following statement in response to an announcement
issued October 9, 2012, by AFH Holding & Advisory, LLC.

Continue reading...

Emmaus Medical Marks Progression of Phase 3 Sickle Cell Disease Clinical Trial

09.14.2012.

TORRANCE, Calif., September 13, 2012 –In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.

Continue reading...